Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major histocompatibility complex, class II, DP alpha 1 (HLA-DPA1) is the alpha-chain subunit of the HLA-DP molecule, a heterodimeric MHC class II cell surface receptor expressed on antigen-presenting cells such as B lymphocytes, dendritic cells, and macrophages[1][4][5]. Together with its beta-chain partner (HLA-DPB1), it binds peptides derived from extracellular antigens and presents them to CD4+ T lymphocytes, playing a crucial role in adaptive immune responses and immune regulation[1][2][4]. The gene encoding HLA-DPA1 is highly polymorphic, contributing to the diversity of immune recognition[2]; specific alleles of HLA-DPA1 have been associated with susceptibility to autoimmune conditions, infectious disease outcomes, and transplantation compatibility[2][3]. Because of its central function in antigen presentation, HLA-DPA1 is a critical immunological target in clinical contexts such as transplantation, vaccine response, autoimmunity, and infectious diseases[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major histocompatibility complex, class II, DP alpha 1 (HLA-DPA1).